ERBB2 and breast cancer: Based on these data, PAM50 subtypes are positioned as a useful tool for evaluating by pCR achievement prediction, the response to NAC, and in the case of HER2+ BC, the response to NAC+anti-HER2 target therapies, with the general consensus of HER2-enriched and basal-like subtypes predicting higher pCR rates, and luminal A tumors predicting the lowest rates (Table 2).